- Roman Fischer of Oxford University demonstrates high-throughput 4D proteomics我non-depleted,未经处理的等离子体dentifying >350 protein groups with short 10-20 minute methods, enabling high throughput, robust biomarker discovery
- OmicEra Diagnostics reports running 720 undepleted serum samples from 31 COVID-19 patients over just 12 days on a single timsTOF Pro system at a rate of 60 samples/day, with 502 proteins quantified and 116 proteins with significant changes in expression levels
- TIMS/PASEF使用SEER Proteograph™产品套件处理血浆样品，可产生前所未有的深度，速度和可扩展性，并鉴定> 1,700个蛋白质组
- PaSER software version 1.1 released, including performance enhancements and visualization of Mobility-Offset Mass-Aligned (MOMA) analysis in 4D proteomics
- 启动了可富有的Phox交联和三个可切合的交联，分析了最大和Xlinkx在结构蛋白质组学和蛋白质蛋白质相互作用（PPI）研究中支持的TIMSTOF交联数据（PPI）研究
BILLERICA, Mass.--(BUSINESS WIRE)-- At the virtual 17thUS HUPO Conference (US HUPO 2021),Bruker Corporation（纳斯达克：BRKR）today announces progress with several collaborations in deep, unbiased plasma proteomics, leveraging the speed, sensitivity and dynamic range of 4D proteomics on timsTOF Pro systems.
该新闻稿具有多媒体。在此处查看完整版本：https://www.businesswire.com/news/home/20210308005537/en/
New results from a key collaborator, Professor Kirk Hansen of the University of Colorado Anschutz Medical Center, will be presented at Bruker’s virtual seminar at US HUPO on Tuesday, March 9that 2:00 p.m. EST. Registration for the US HUPO Conference is required to attend the event live. Dr. Hansen will present studies of the plasma proteomes of patients infected with COVID-19, as well as a large-cohort comparison of plasma proteome changes in trauma patients.
Dr. Hansen’s research reveals protein dynamics in acute injury and disease states with tens of thousands of measurements per sample. Running larger clinical cohorts is illuminating molecular relationships and mechanistic understanding that has the potential to go well beyond current diagnostics.
汉森教授评论说：“我们直到最近才重新进入血浆蛋白质组学空间，这主要是由于timstof Pro的速度，敏感性和吞吐量。加上Evosep One，该系统提供了几年前我们无法实现的可靠性和吞吐量。”
在2021年初，布鲁克宣布了曼恩组的突破性论文，该论文展示了无偏见的，定量的真实单细胞蛋白质组学，以解决单细胞生物学和病理学中的重要问题（www.biorxiv.org/content/10.1101/2020.12.22.423933v1). Bruker intends to launch a high-end, dedicated single-celltimsTOF2022年初的系统用于无偏定量的单细胞蛋白质组学。
Bruker recently announced a newNature Communicationspublication by the Mann & Theis groups on the benefits of large-scale peptide Collisional Cross Section (CCS) measurements and machine learning for 4D proteomics (doi.org/10.1038/s41467-021-21352-8). Harnessing deep learning, CCS values can now be predicted for any peptide from any organism, forming a basis for advanced 4D proteomics workflows that make full use of the additional peptide CCS 4thdimension.
A. PaSER 1.1 Real-Time Proteomics Search
布鲁克释放它PaSERsoftware v.1.1, which Dr. Chris Adams, Director of Proteomics Business Development at Bruker Daltonics, will present during the US HUPO seminar on March 9th. PaSER is GPU-based and enables proteomics database search in real time, building on Bruker’s acquisition ofIP2software. ‘PaSER’ stands forParallelS耳朵Engine inREAL时间，在GPU上进行并行的多线程搜索，以获得比数据采集的速度更快的结果。这允许“运行和完成”高通量4D蛋白质组学，一旦实验完成，就可以使用已鉴定的肽和蛋白质基团。
In addition to performance enhancements, PaSER 1.1 includes visualization of 4D data, including MOMA features and search results. A powerful feature of 4D proteomics is Mobility-Offset Mass-Aligned (MOMA) analysis, where co-eluting isomeric or isobaric ions, which cannot be distinguished in typical 3D proteomics, are resolved by mobility separation with precise Collision Cross Sections (CCS) at scale.
B.结构蛋白质组学和蛋白质蛋白质相互作用（PPI）的交联
布鲁克宣布发布新的消耗品和软件，用于研究蛋白质结构和相互作用的蛋白质化学交联（XL-MS）。艾伯特·赫克（Albert Heck）和理查德·谢尔特玛（Richard Scheltema）的发展后，弗洛克大学（Phox Cross-Linker）将于今年春天从布鲁克（Bruker）商业上获得，并从乌得勒支（Utrecht）获得许可。Phox是一种具有磷酸基团的可富集交联，它允许使用金属珠亲和力纯化从XL-MS反应产生的复杂混合物中纯化。这种富集极大地增强了检测交联肽的能力，并在Albert Heck，Richard Scheltema和Bruker群体之间进行了协作工作，这表明，使用CAPS-PASEF（通过CAPS-PASEF）可以通过TIMS分离来增强交联检测（MCP, 20 Jul 2020, 19(10):1677-1687). Bruker will also launch 3 cleavable cross-linkers in the spring, which are preferred by some research groups, as cleavage of cross-linkers in MS/MS experiments results in characteristic mass differences that are easily detected.
化学交联数据非常复杂，需要自动分析软件。流行的新版本MaxQuant来自德国Martinsried的Max Planck Institute的Juergen Cox教授小组的软件也支持对Timstof Pro Systems的XL-MS数据的分析。它是在Beta测试中，预计将于2021年4月发行，以利用XL-MS工作的4D蛋白质组学。
C. Progress in Deep, Unbiased Plasma Proteomics
Several research groups have recently presented exciting results on plasma proteomics using a variety of methods.
In February 2021, Professor Roman Fischer of the Target Discovery Institute in the Nuffield Department of Medicine at Oxford University presented “高通量蛋白质组学在G大流行期间”enetic Engineering & Biotech News (genengnews.com). Dr. Fischer discusses high-throughput 4D proteomics of several hundred undepleted plasma samples from COVID-19 patients with different disease severity, healthy controls and patients suffering from other pathologies, like sepsis.
Also in February 2021, researchers from OmicEra Diagnostics GmbH in Planegg, Germany, posted a manuscript on MedRxiv “High-resolution longitudinal serum proteome trajectories in COVID-19 reveal patients-specific seroconversion”，其中使用高通量4D蛋白质组学，平均31例纵向跟踪31天。这项研究采用了Omicera的自动蛋白质组学管道，再加上Evosep One色谱系统运行21分钟的梯度，每天实现60个样品的吞吐量。
使用这种方法，Omicera在12天内在单个Timstof Pro上运行了720种未耗尽的血清样品，总共定量了502种蛋白质。大约116种蛋白质的表达水平有定量变化。在美国Hupo，Bruker在与Omicera的合作工作中发布了有关血清蛋白质组学的申请说明。
At US HUPO 2021, Seer (www.seer.bio) will present a collaborative poster with Bruker, showing the unique capabilities of Seer’s engineered nanoparticles in combination with the TIMS/PASEF methods. Together, this strategy achieved unbiased, deep and rapid plasma proteome analysis with >1,700 protein groups identified with 90-minute DDA nanoLC-TIMS-MS/MS methods. The combination of Seer’s Proteograph Product Suite with the TIMS/PASEF method provides a scalable solution for unbiased and deep proteomics, accessible to nearly any lab, for the first time.
Dr. Chris Adams, Director of Proteomics Business Development at Bruker Daltonics, stated: “It has been rewarding to see the recent rapid advances in the field of plasma proteomics, an area we expect to grow rapidly in liquid biopsy multiomics translational research and biomarker validation. These advances in deep, unbiased plasma proteomics are enabled by the throughput, robustness and unique 4D proteomics selectivity and sensitivity advantages of TIMS/PASEF methods.”
可以在此处找到指向Bruker活bob综合客户端app动的链接到2021年Virtual US HUPO会议。//www.energie2point0.com/en/landingpages/bdal/us-hupo.html.
About Bruker Corporation（纳斯达克：BRKR）
布鲁克（Bruker）使科学家能够做出突破性的发现，并开发新的应用，以改善人类生活的质量。布鲁克的高性能科学工具以及高价值的分析和诊断解决方案使科学家能够在分子，细胞和微观水平上探索生命和材料。bob综合游戏在与我们的客户密切合作的情况下，布鲁克正在实现创新，提高生命科学分子和细胞生物学研究，应用和制药应用，显微镜和纳米分析以及工业应用方面的生产率和客户成功。bob娱乐平台Bruker在临床前成像，临床现象学研究，蛋白质组学和多组学，空间和单细胞生物学，功能结构和凝结生物学以及临床微生物学和分子诊断中提供了差异化的高价值生命科学和诊断系统和解决方案。有关更多信息，请访问：www.energie2point0.com.
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20210308005537/en/
Media Contact:
Petra Scheffer
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E：[email protected]
Investor Contact:
Miroslava Minkova
Director of Investor Relations & Corporate Development
T: +1 (978) 663-3660, ext. 1479
E：[email protected]
Source: Bruker Corporation